Salicylic acid with rhubarb extract
A topical paint combining salicylic acid with rhubarb extract, traditionally used as a keratolytic and astringent preparation for the treatment of warts and verrucae.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Salicylic acid provides the principal keratolytic action by softening and dissolving hyperkeratotic skin, while the rhubarb extract contributes an astringent, staining effect; the combined action gradually erodes the wart tissue.
Prescribing in practice
- Apply only to the lesion and protect surrounding healthy skin, as the salicylic acid can cause chemical irritation and damage to normal skin.
- Avoid application to the face, anogenital area and broken skin, and avoid use on warts in patients with diabetes or impaired peripheral circulation.
- The preparation stains skin and may stain clothing, so apply carefully and allow to dry.
Monitoring
No laboratory monitoring is needed; inspect the treated area periodically for irritation and treatment response.
Counselling the patient
- Apply the paint accurately to the wart only and avoid the surrounding skin.
- Expect temporary staining of the treated skin; persist with regular application over several weeks.
- Stop and seek advice if the skin becomes sore, broken or inflamed.
Evidence & guidelines
Topical salicylic acid is the evidence-based active in such wart paints, with the additional botanical component being a traditional formulation adjunct.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Tumor Lysis Syndrome Risk (Cairo-Bishop) · Oncological Emergency
- FAST Exam Protocol — Focused Assessment with Sonography in Trauma · Trauma
- Urine Anion Gap · Acid-Base
- Bicarbonate Deficit Calculator · Acid-Base
- Delta Ratio for Mixed Acid-Base Disorders · Acid-Base
- Expected PaCO₂ in Metabolic Acidosis (Winter's Formula) · Acid-Base
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD